Histogenics Corporation

The momentum for this stock is not very good. Histogenics Corporation is not very popular among insiders. Histogenics Corporation is a mediocre stock to choose.
Log in to see more information.
OCGN Fundamental Data by TradingView

News

Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

Globe Newswire MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ( Ocugen or the Company ) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...\n more…

Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit

Globe Newswire MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...\n more…

Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire MALVERN, Pa., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...\n more…

Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST A Modifier Gene Therapy
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST A Modifier Gene Therapy

Globe Newswire MALVERN, Pa., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ( Ocugen or the Company ) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...\n more…

Ocugen announces Health Canada sent "No Objection Letter" for OCU400 trial
Ocugen announces Health Canada sent "No Objection Letter" for OCU400 trial

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Globe Newswire MALVERN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ( Ocugen or the Company ) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...\n more…